Taiwan · Delayed Price · Currency is TWD BioLASCO Taiwan Statistics
Total Valuation
BioLASCO Taiwan has a market cap or net worth of TWD 760.68 million. The enterprise value is 722.08 million.
| Market Cap | 760.68M |
| Enterprise Value | 722.08M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Aug 7, 2025 |
Share Statistics
BioLASCO Taiwan has 25.61 million shares outstanding. The number of shares has increased by 0.28% in one year.
| Current Share Class | 25.61M |
| Shares Outstanding | 25.61M |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | -1.45% |
| Owned by Insiders (%) | 29.84% |
| Owned by Institutions (%) | n/a |
| Float | 15.89M |
Valuation Ratios
The trailing PE ratio is 17.60.
| PE Ratio | 17.60 |
| Forward PE | n/a |
| PS Ratio | 2.88 |
| PB Ratio | 1.81 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | 23.96 |
| P/OCF Ratio | 14.00 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.43, with an EV/FCF ratio of 22.74.
| EV / Earnings | 16.64 |
| EV / Sales | 2.74 |
| EV / EBITDA | 11.43 |
| EV / EBIT | 14.52 |
| EV / FCF | 22.74 |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.33 |
| Quick Ratio | 1.94 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 1.43 |
| Debt / FCF | 2.84 |
| Interest Coverage | 24.32 |
Financial Efficiency
Return on equity (ROE) is 10.33% and return on invested capital (ROIC) is 10.76%.
| Return on Equity (ROE) | 10.33% |
| Return on Assets (ROA) | 5.20% |
| Return on Invested Capital (ROIC) | 10.76% |
| Return on Capital Employed (ROCE) | 9.93% |
| Weighted Average Cost of Capital (WACC) | 4.86% |
| Revenue Per Employee | 2.90M |
| Profits Per Employee | 476,824 |
| Employee Count | 91 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 5.36 |
Taxes
In the past 12 months, BioLASCO Taiwan has paid 7.47 million in taxes.
| Income Tax | 7.47M |
| Effective Tax Rate | 14.69% |
Stock Price Statistics
The stock price has decreased by -14.90% in the last 52 weeks. The beta is 0.17, so BioLASCO Taiwan's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -14.90% |
| 50-Day Moving Average | 29.54 |
| 200-Day Moving Average | 30.58 |
| Relative Strength Index (RSI) | 51.51 |
| Average Volume (20 Days) | 3,563 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLASCO Taiwan had revenue of TWD 263.81 million and earned 43.39 million in profits. Earnings per share was 1.69.
| Revenue | 263.81M |
| Gross Profit | 106.05M |
| Operating Income | 49.46M |
| Pretax Income | 50.86M |
| Net Income | 43.39M |
| EBITDA | 61.68M |
| EBIT | 49.46M |
| Earnings Per Share (EPS) | 1.69 |
Balance Sheet
The company has 128.85 million in cash and 90.26 million in debt, with a net cash position of 38.59 million or 1.51 per share.
| Cash & Cash Equivalents | 128.85M |
| Total Debt | 90.26M |
| Net Cash | 38.59M |
| Net Cash Per Share | 1.51 |
| Equity (Book Value) | 420.05M |
| Book Value Per Share | 16.40 |
| Working Capital | 118.04M |
Cash Flow
In the last 12 months, operating cash flow was 54.32 million and capital expenditures -22.57 million, giving a free cash flow of 31.75 million.
| Operating Cash Flow | 54.32M |
| Capital Expenditures | -22.57M |
| Depreciation & Amortization | 12.23M |
| Net Borrowing | -17.41M |
| Free Cash Flow | 31.75M |
| FCF Per Share | 1.24 |
Margins
Gross margin is 40.20%, with operating and profit margins of 18.75% and 16.45%.
| Gross Margin | 40.20% |
| Operating Margin | 18.75% |
| Pretax Margin | 19.28% |
| Profit Margin | 16.45% |
| EBITDA Margin | 23.38% |
| EBIT Margin | 18.75% |
| FCF Margin | 12.03% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 5.10%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 5.10% |
| Dividend Growth (YoY) | -9.09% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 88.54% |
| Buyback Yield | -0.28% |
| Shareholder Yield | 4.83% |
| Earnings Yield | 5.70% |
| FCF Yield | 4.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 30, 2018. It was a forward split with a ratio of 1.055.
| Last Split Date | Jul 30, 2018 |
| Split Type | Forward |
| Split Ratio | 1.055 |
Scores
BioLASCO Taiwan has an Altman Z-Score of 4.18 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.18 |
| Piotroski F-Score | 6 |